187 related articles for article (PubMed ID: 37271662)
1. Characterizing Outcomes in Visceral Cutaneous T-Cell Lymphoma: A Single Center Retrospective Study.
Zhuang TZ; McCook-Veal A; Switchenko J; Niyogusaba T; Tarabadkar ES; Baird K; O'Leary C; Paulino D; Lechowicz MJ; Allen PB
Clin Lymphoma Myeloma Leuk; 2023 Sep; 23(9):667-673. PubMed ID: 37271662
[TBL] [Abstract][Full Text] [Related]
2. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
3. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic Features of Cutaneous T-Cell Lymphomas With Extracutaneous Metastasis: A Case Series.
Tang H; Matsumoto N; Foss F; Xu M; Ahmed A
Clin Lymphoma Myeloma Leuk; 2023 Nov; 23(11):e405-e410. PubMed ID: 37659965
[TBL] [Abstract][Full Text] [Related]
5. Primary Cutaneous Lymphomas in Thailand: A 10-Year Retrospective Study.
Pruksaeakanan C; Teyateeti P; Patthamalai P; Thumrongtharadol J; Chairatchaneeboon M
Biomed Res Int; 2021; 2021():4057661. PubMed ID: 34235215
[TBL] [Abstract][Full Text] [Related]
6. Bridging the specialty gap: Update on primary cutaneous lymphomas.
Olsen EA; Hodak E; Geskin L; Scarisbrick J;
J Am Acad Dermatol; 2024 Feb; 90(2):257-260. PubMed ID: 38043039
[No Abstract] [Full Text] [Related]
7. Primary cutaneous T-cell lymphomas other than mycosis fungoides and Sézary syndrome. Part II: Prognosis and management.
Oh Y; Stoll JR; Moskowitz A; Pulitzer M; Horwitz S; Myskowski P; Noor SJ
J Am Acad Dermatol; 2021 Nov; 85(5):1093-1106. PubMed ID: 33945836
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous T cell lymphomas: mycosis fungoides, Sezary syndrome and HTLV-I-associated adult T cell leukemia (ATL) in Mali, West Africa: a clinical, pathological and immunovirological study of 14 cases and a review of the African ATL cases.
Fouchard N; Mahe A; Huerre M; Fraitag S; Valensi F; Macintyre E; Sanou F; de The G; Gessain A
Leukemia; 1998 Apr; 12(4):578-85. PubMed ID: 9557617
[TBL] [Abstract][Full Text] [Related]
9. Clinical Presentation and Outcome Differences Between Black Patients and Patients of Other Races and Ethnicities With Mycosis Fungoides and Sézary Syndrome.
Allen PB; Goyal S; Niyogusaba T; O'Leary C; Ayers A; Tarabadkar ES; Khan MK; Lechowicz MJ
JAMA Dermatol; 2022 Nov; 158(11):1293-1299. PubMed ID: 36069854
[TBL] [Abstract][Full Text] [Related]
10. Evaluation, Diagnosis, and Staging of Cutaneous Lymphoma.
Olsen EA
Dermatol Clin; 2015 Oct; 33(4):643-54. PubMed ID: 26433839
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression.
Kim YH; Liu HL; Mraz-Gernhard S; Varghese A; Hoppe RT
Arch Dermatol; 2003 Jul; 139(7):857-66. PubMed ID: 12873880
[TBL] [Abstract][Full Text] [Related]
12. Expression of T-follicular helper markers in sequential biopsies of progressive mycosis fungoides and other primary cutaneous T-cell lymphomas.
Bosisio FM; Cerroni L
Am J Dermatopathol; 2015 Feb; 37(2):115-21. PubMed ID: 25406852
[TBL] [Abstract][Full Text] [Related]
13. Understanding Cell Lines, Patient-Derived Xenograft and Genetically Engineered Mouse Models Used to Study Cutaneous T-Cell Lymphoma.
Gill RPK; Gantchev J; Martínez Villarreal A; Ramchatesingh B; Netchiporouk E; Akilov OE; Ødum N; Gniadecki R; Koralov SB; Litvinov IV
Cells; 2022 Feb; 11(4):. PubMed ID: 35203244
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive analysis of cutaneous T-cell lymphoma (CTCL) incidence and mortality in Canada reveals changing trends and geographic clustering for this malignancy.
Ghazawi FM; Netchiporouk E; Rahme E; Tsang M; Moreau L; Glassman S; Provost N; Gilbert M; Jean SE; Pehr K; Sasseville D; Litvinov IV
Cancer; 2017 Sep; 123(18):3550-3567. PubMed ID: 28493286
[TBL] [Abstract][Full Text] [Related]
15. Impact of blood involvement on efficacy and time to response with mogamulizumab in mycosis fungoides and Sézary syndrome.
Beylot-Barry M; Booken N; Weishaupt C; Scarisbrick J; Wu W; Rosen JP; Medley MC
J Eur Acad Dermatol Venereol; 2023 Feb; 37(2):311-316. PubMed ID: 35993803
[TBL] [Abstract][Full Text] [Related]
16. [Rare variants of cutaneous T-cell lymphomas].
Goerdt S; Trautmann C; Kütting B; Ramaker J; Schmuth M; Thiel E; Luger T; Stein H; Orfanos CE
Hautarzt; 1996 Feb; 47(2):96-105. PubMed ID: 8868452
[TBL] [Abstract][Full Text] [Related]
17. Cutaneous T-cell lymphoma. Refinement in the application of controversial histologic criteria.
Glusac EJ; Shapiro PE; McNiff JM
Dermatol Clin; 1999 Jul; 17(3):601-14, ix. PubMed ID: 10410861
[TBL] [Abstract][Full Text] [Related]
18. T-Cell Receptor Gene Rearrangement Clonality, Flow Cytometry Status, and Associated Outcomes in Early-Stage Cutaneous T-Cell Lymphoma.
Marks JA; Switchenko JM; Martini DJ; Tarabadkar ES; Khan MK; Lechowicz MJ; Allen PB
JAMA Dermatol; 2021 Aug; 157(8):954-962. PubMed ID: 34190977
[TBL] [Abstract][Full Text] [Related]
19. Total Skin Electron Beam for Primary Cutaneous T-cell Lymphoma.
Elsayad K; Kriz J; Moustakis C; Scobioala S; Reinartz G; Haverkamp U; Willich N; Weishaupt C; Stadler R; Sunderkötter C; Eich HT
Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):1077-86. PubMed ID: 26581145
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics, prognostic factors, and survival of 393 patients with mycosis fungoides and Sézary syndrome in the southeastern United States: a single-institution cohort.
Desai M; Liu S; Parker S
J Am Acad Dermatol; 2015 Feb; 72(2):276-85. PubMed ID: 25458019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
